How do immune checkpoint inhibitors work for patients with liver metastases?
Liver metastases are a common and challenging complication in many cancers. Immune checkpoint inhibitors (ICIs) work by blocking proteins that stop the immune system from attacking cancer cells. However, the liver's unique immune environment can make ICIs less effective when cancer spreads there. Research suggests that patients with liver metastases often have worse responses to ICI therapy, but combining ICIs with other treatments may help overcome this resistance.
What the research says
Several studies indicate that the presence of liver metastases can dampen the effectiveness of ICIs. For example, in metastatic colorectal cancer, combining a VEGF receptor tyrosine kinase inhibitor (zanzalintinib) with the ICI atezolizumab showed promise, particularly in patients without liver metastases, suggesting that liver metastases may limit ICI benefit 11. Similarly, in triple-negative breast cancer, the IMpassion131 trial found that adding atezolizumab to paclitaxel did not improve progression-free survival in the overall population, and subgroup analyses suggested that patients with liver metastases had worse outcomes 9.
Combination strategies may help. In hepatocellular carcinoma, adding local treatments like transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) to ICIs and tyrosine kinase inhibitors improved disease control rates compared to ICIs plus TKIs alone 4. This suggests that local therapy can enhance ICI efficacy, possibly by altering the tumor microenvironment.
Additionally, emerging approaches like nanomedicine delivery systems are being explored to improve ICI delivery and effectiveness in colorectal cancer, which may benefit patients with liver metastases 2. However, more research is needed to confirm these benefits in liver metastasis patients specifically.
What to ask your doctor
- Given my liver metastases, what is the expected benefit of immune checkpoint inhibitors for my cancer type?
- Are there combination treatments, such as local therapy or targeted drugs, that could improve the effectiveness of immunotherapy for me?
- Should I consider a clinical trial testing new ICI combinations for patients with liver metastases?
- How will we monitor my response to treatment, and what signs might indicate that the immunotherapy is not working?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.